Patent · US Active

Fc-epsilon car

US11643452B2 · kind B2 · utility

1Cited by
14References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 7, 2021
Grant dateMay 9, 2023
Priority date
Expiry dateAug 10, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.